DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

Phase 4

Completed

Conditions: Episodic Migraine

Interventions: Drug: AMG334
Drug: Oral Prophylactic

First Posted Date: 2019-04-25

Last Posted Date: 2023-11-18

Lead Sponsor: Amgen

Target Recruit Count: 621

Registration Number: NCT03927144

Locations: 🇨🇿
NEUROHK sro, Chocen, Czechia
🇺🇸
Stanford Headache Center, Stanford, California, United States
🇧🇪
Centre Hospitalier Regional de la Citadelle, Liege, Belgium

and more 109 locations

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Phase 4

Terminated

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Erenumab

First Posted Date: 2019-04-11

Last Posted Date: 2022-07-20

Lead Sponsor: Amgen

Target Recruit Count: 29

Registration Number: NCT03912337

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Phase 1

Withdrawn

Conditions: Relapsed/Refractory Acute Myeloid Leukemia

Interventions: Drug: AMG 553

First Posted Date: 2019-04-04

Last Posted Date: 2023-06-12

Lead Sponsor: Amgen

Registration Number: NCT03904069

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Phase 3

Active, not recruiting

Conditions: Coronary Heart Disease (CHD)

Interventions: Drug: Placebo
Drug: Evolocumab

First Posted Date: 2019-03-13

Last Posted Date: 2025-02-07

Lead Sponsor: Amgen

Target Recruit Count: 12301

Registration Number: NCT03872401

Locations: 🇺🇸
Nature Coast Clinical Research LLC, Crystal River, Florida, United States
🇺🇸
Multicare Institute for Research and Innovation, Puyallup, Washington, United States
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 839 locations

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2019-03-01

Last Posted Date: 2024-08-13

Lead Sponsor: Amgen

Target Recruit Count: 454

Registration Number: NCT03859427

Locations: 🇺🇸
Oncology Consultants PA, Houston, Texas, United States
🇳🇱
Gelre Ziekenhuizen, Apeldoorn, Netherlands
🇳🇱
Spaarne Gasthuis, Hoofddorp, Netherlands

and more 105 locations

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Phase 2

Completed

Conditions: Hidradenitis Suppurativa
Acne Inversa

Interventions: Other: Placebo
Drug: Avacopan

First Posted Date: 2019-02-25

Last Posted Date: 2025-03-17

Lead Sponsor: Amgen

Target Recruit Count: 435

Registration Number: NCT03852472

Locations: 🇺🇸
Clinical Site, Morgantown, West Virginia, United States

AMG 404 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: AMG 404

First Posted Date: 2019-02-25

Last Posted Date: 2024-12-13

Lead Sponsor: Amgen

Target Recruit Count: 171

Registration Number: NCT03853109

Locations: 🇵🇱
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇧🇷
Instituto Coi, Rio de Janeiro, Brazil

and more 31 locations

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: AMG 420

First Posted Date: 2019-02-11

Last Posted Date: 2024-01-05

Lead Sponsor: Amgen

Target Recruit Count: 23

Registration Number: NCT03836053

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇦🇺
St Vincents Hospital Melbourne, Fitzroy, VIC, Victoria, Australia
🇨🇭
Kantonsspital St Gallen, St. Gallen, Switzerland

and more 7 locations

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Erenumab Dose 1
Other: Placebo
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

First Posted Date: 2019-02-11

Last Posted Date: 2025-05-22

Lead Sponsor: Amgen

Target Recruit Count: 456

Registration Number: NCT03836040

Locations: 🇨🇴
Fundacion Centro de Investigacion Clinica, Medellín, Antioquia, Colombia
🇺🇸
Paradigm Clinical Research Center Inc, San Diego, California, United States
🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States

and more 115 locations

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

Phase 3

Active, not recruiting

Conditions: Migraine

Interventions: Drug: Erenumab Dose 1
Other: Placebo
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

First Posted Date: 2019-02-06

Last Posted Date: 2025-01-15

Lead Sponsor: Amgen

Target Recruit Count: 284

Registration Number: NCT03832998

Locations: 🇺🇸
Paradigm Clinical Research Center Inc, San Diego, California, United States
🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States

and more 98 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy